|12. In adults with active AS despite treatment with the first TNFi used, we conditionally recommend treatment with a different TNFi over treatment with a non-TNFi biologic in patients with secondary nonresponse to TNFi.|Very low|10|
|13. In adults with active AS despite treatment with the first TNFi used, we strongly recommend against switching to treatment with a biosimilar of the first TNFi.|Very low|62|
|14. In adults with active AS despite treatment with the first TNFi used, we conditionally recommend against the addition of sulfasalazine or methotrexate in favor of treatment with a new biologic.|Very low|9|
|15. We strongly recommend against treatment with systemic glucocorticoids.†|Very low|4|
|16. In adults with isolated active sacroiliitis despite treatment with NSAIDs, we conditionally recommend treatment with locally administered parenteral glucocorticoids over no treatment with local glucocorticoids.†|Very low|13|